Jonathan MD - Neoleukin Therapeutics President, CEO

Insider

Jonathan MD is President, CEO of Neoleukin Therapeutics
Age 61
Phone855 226 6447
Webhttps://www.neoleukin.com

Neoleukin Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.1871) % which means that it has lost $0.1871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3788) %, meaning that it created substantial loss on money invested by shareholders. Neoleukin Therapeutics' management efficiency ratios could be used to measure how well Neoleukin Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Neoleukin Therapeutics currently holds 12.07 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Neoleukin Therapeutics has a current ratio of 12.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Neoleukin Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Julia WilsonAchilles Therapeutics PLC
N/A
Angela MDSpero Therapeutics
N/A
Ian CritchleySpero Therapeutics
N/A
Iraj AliAchilles Therapeutics PLC
50
Ted JenkinsSpero Therapeutics
N/A
Adam ZlotnickAssembly Biosciences
N/A
Karl MDAchilles Therapeutics PLC
57
Gary HattersleyNuvation Bio
58
Satyavrat CFASpero Therapeutics
52
Kim BlickenstaffNuvation Bio
68
Timothy MooreInstil Bio
63
Hoyoung MDCytomX Therapeutics
56
Kerry WentworthNuvation Bio
52
Oleg NodelmanNuvation Bio
44
Sergio QuezadaAchilles Therapeutics PLC
49
AO FRACPAssembly Biosciences
65
MBA MDSpero Therapeutics
44
Thomas TemplemanNuvation Bio
60
Mark DudleyInstil Bio
N/A
Kathryn FalbergNuvation Bio
60
Sandeep MDInstil Bio
56
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Neoleukin Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 79 people. Neoleukin Therapeutics (NLTX) is traded on NASDAQ Exchange in USA and employs 7 people.

Management Performance

Neoleukin Therapeutics Leadership Team

Elected by the shareholders, the Neoleukin Therapeutics' board of directors comprises two types of representatives: Neoleukin Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neoleukin. The board's role is to monitor Neoleukin Therapeutics' management team and ensure that shareholders' interests are well served. Neoleukin Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neoleukin Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Umut Ulge, VP Devel
MS MD, Chief Officer
Donna JD, Gen Legal
Carl Walkey, Sr Devel
Bill Arthur, VP Research
Sean Smith, VP Officer
Kamran Alam, CFO, Vice President - Finance
David Baker, Cofounder Board
Jonathan MD, President, CEO

Neoleukin Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neoleukin Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Other Consideration for investing in Neoleukin Stock

If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Transaction History
View history of all your transactions and understand their impact on performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins